Stock market news

Biogen

Biogen's GAAP net income for 9 months of 2023 was $0.913 billion, down 2.6 times from $2.412 billion in the prior year. Revenue declined 2.4% to $7.449 billion from $7.629 billion a year earlier.

Yakovlev

Yakovlev's shareholders approved an increase in the authorized capital by placing 32 billion additional shares by private subscription in favor of a classified circle of persons. Payment for the shares may be made either in cash and property or by offsetting counter monetary claims.

Samaraenergo

Samaraenergo's RAS net profit for 9 months of 2023 amounted to ₽1.033 billion, up 19% from ₽0.868 billion in the previous year. Revenue rose 10.3% to ₽32.484 billion against ₽29.438 billion a year earlier.

Vladimir Chemical Plant

Vladimir Chemical Plant's RAS net profit for 9 months of 2023 amounted to ₽133.04 million, up 2.8 times from ₽48.14 million in the previous year. Revenue rose 8.1% to ₽2.852 billion against ₽2.639 billion a year earlier.

Henderson

Henderson's revenue for 9 months amounted to ₽10.91 billion, up 31% from ₽8.35 billion a year earlier. LFL sales were up 26%. Retail space increased 18.8% to 46,635 square meters.

Lipetsk Energy Supply Company

Lipetsk Power Supply Company's RAS net profit for 9 months of 2023 amounted to ₽986.06 million, up 96.5% from ₽501.84 million in the previous year. Revenue increased 6.1% to ₽10.611 billion against ₽10 billion a year earlier.

Ozon Holdings

Ozon has sent the Ministry of Economic Development proposals and comments to the draft law on marketplaces. Company proposes to adjust practically all the key points of the draft law, since in its current form it threatens to abolish the business model of marketplaces. In particular, a number of clauses of the bill actually equate marketplaces with retail ch...

Sberbank

Sberbank intends to create its own cross-bank bio-acquiring platform to which other banks will be able to connect, the bank's head Herman Gref said. Cross-banking platform will be created on the basis of the Sberbank's platform for bioacquiring, which is already used by millions of customers.

Gilead Sciences

Gilead Sciences' GAAP net income for 9 months of 2023 was $4.196 billion, up 43.1% from $2.933 billion in the prior year. Revenues increased 0.5% to $20 billion from $19.892 billion a year earlier.

Gilead Sciences

Gilead Sciences Board of Directors announced a quarterly dividend of $0.75 per share. The last day to buy securities to receive the dividend is December 13, 2023. The annual dividend yield may reach 3.8%.